Related Experiment Video
Updated: Aug 27, 2025
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
The Outcome of Hodgkin Lymphoma With Reference to Prognostic Markers
Rehana Ahmed1, Faryal Tariq1, Javeria Ashfaq2
1Clinical Hematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, PAK.
Objectives:
This study aimed to determine the impact of prognostic markers on the outcomes of Hodgkin lymphoma.
Methods:
It is a cross-sectional, single-center study. A total of 60 patients diagnosed with Hodgkin lymphoma were recruited for the study over five years between 2016 to 2020. The study setting was the National Institute of Blood and Bone Marrow Transplant in Pakistan. The Statistical Package for Social Sciences (SPSS) version 23 (IBM Corp., Armonk, NY, USA) was used for statistical analysis.
Results:
In the study population, 63.3% of the patients were male (38/60), and 36.7% were female (22/60). Hodgkin lymphoma was divided into four stages: stage I (18.3%), stage II (18.3%), stage III (46.7%), and stage IV (16.7%). Patients in stage III had a higher value of hemoglobin (Hb) than in other stages of the disease. The erythrocyte sedimentation rate was high in 56.7% of stage III patients than in patients of the other stages. The lactate dehydrogenase (LDH) levels were not under the normal range in 51.6% of patients. Only 20% of patients in stage III had LDH values within the normal range, whereas 26.6% did not.
Conclusion:
There was a significant impact of prognostic factors on the survival of patients with Hodgkin lymphoma.
